-
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
30 Aug 2024 15:40 GMT
… messenger RNA (mRNA) – the genetic precursors that encode for disease … of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY … successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to successfully …
-
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
07 Aug 2024 22:23 GMT
… messenger RNA (mRNA) – the genetic precursors that encode for disease … of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY … successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to successfully …
-
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
01 Aug 2024 14:01 GMT
… messenger RNA (mRNA) – the genetic precursors – that encode for disease … of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq … execute on its “Alnylam P5x25” strategy; Alnylam’s ability to discover …
-
It’s happy hour (for now) for Alnylam
17 Jul 2024 16:16 GMT
… another one in a rare genetic condition that causes people’s … hour (for now) for Alnylam
Shares of Alnylam have been riding high … next month, but for now, Alnylam’s founding CEO John Maraganore … for every $50 increase in Alnylam’s share price. It does …
-
What’s Next For Alnylam Stock After A 60% Rise In A Week?
28 Jun 2024 11:22 GMT
… this photo illustration, the Alnylam Pharmaceuticals logo seen on … 47;LightRocket via Getty Images
Alnylam Pharmaceuticals stock (NASDAQ: … RNA interference therapeutics for genetically defined diseases, has seen … and Oxlumo. With Alnylam pushing for Amvuttra’s …
-
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
24 Jun 2024 15:11 GMT
Alnylam reported a successful Phase … Shutterstock.com
Heart disease drugmaker Alnylam (NASDAQ:ALNY) stock rose … 28 billion.
Heart Disease Hope
Alnylam CEO Yvonne Greenstreet called the … electrocardiogram (ECG), this can include genetic tests.
ALNY Stock: What …
-
Alnylam shares surge as biotech trumpets positive trial results of heart disease drug
24 Jun 2024 14:24 GMT
Alnylam Pharmaceuticals said Monday that a drug to treat a rare genetic … cardiomyopathy,” said Yvonne Greenstreet, Alnylam’s chief executive, in a … of this disease, driving Alnylam’s next era of … brand name Amvuttra. Like Alnylam’s other approved drugs, …
-
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
24 Jun 2024 11:15 GMT
… messenger RNA (mRNA) – the genetic precursors that encode for disease … of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY … successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to successfully …
-
A Closer Look at Alnylam Pharmaceuticals's Options Market Dynamics
21 Jun 2024 17:00 GMT
… .0K
711
209
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader … programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic … partnerships.
Current Position of Alnylam Pharmaceuticals
With a volume of …
-
Mivelsiran by Alnylam Pharmaceuticals for Alzheimer’s Disease: Likelihood of Approval
18 Jun 2024 06:52 GMT
… siRNA conjugate platform.
Alnylam Pharmaceuticals overview
Alnylam Pharmaceuticals (Alnylam) is a biopharmaceutical … drugs in the areas of genetic medicines, hepatic infectious, … America, and Asia-Pacific. Alnylam is headquartered in Cambridge, Massachusetts …